Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer

Core Insights - Heron Therapeutics, Inc. has appointed Mark Hensley as Chief Operating Officer, bringing over fifteen years of experience in the pharmaceutical industry [1][2] - The CEO of Heron, Craig Collard, expressed confidence in Hensley's ability to drive operational efficiency and support the company's growth initiatives [2] - Hensley previously held senior leadership roles at Veloxis Pharmaceuticals, including CEO and COO, and has a strong background in sales and operations [2] Compensation and Inducement Awards - As part of his employment, Hensley will receive inducement awards including a non-statutory stock option for 500,000 shares, 500,000 restricted stock units, and a performance-based stock option for up to 900,000 shares [3] - The inducement options have a 10-year term with a four-year vesting schedule, with 25% vesting on the first anniversary and the remainder vesting monthly over the next three years [3] - The performance-based stock option vests based on achieving certain stock price goals during Hensley's employment [3] Company Overview - Heron Therapeutics is a commercial-stage biotechnology company focused on developing and commercializing therapeutic innovations to improve patient care [4] - The company utilizes advanced science and patented technologies to create a portfolio of products aimed at enhancing the standard of care for acute care and oncology patients [4]